Exosome Therapeutics Market | Industry Analysis | Market Size | 2035

With the advancements in technologies developing targeted drug delivery therapies, the researchers are shifting their focus on exosomes as therapeutic drug interventions and drug delivery carriers. The growing interest in exploring exosomes for therapeutic purposes can be attributed to their ability to enter the respective organs, manifesting best results even in a weakened immune system and be stored for longer periods of time, owing to their greater life span. Driven by the ongoing pace of innovation and sufficient financial support from investors, the exosome therapeutics market is anticipated to witness substantial growth in the foreseen future.

Owing to their potential in effective intracellular shuttling, therapeutic molecular delivery and treatment of multiple disorders, exosomes have garnered significant attention of researchers and industry stakeholders in the past few years

The report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the exosome therapies in the treatment of various diseases. The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the study includes:

• A detailed assessment of the current market landscape of drug developers engaged in the development of exosome therapeutics.
• Detailed profiles of key players involved in the development of exosome therapeutics (shortlisted on the basis of the number of pipeline products).
• Detailed drug profiles of key therapeutics in the highest phase of development.
• A detailed analysis of more than 50 completed, ongoing and planned clinical studies of exosome therapeutics.
• An in-depth analysis of more than 500 academic grants that have been awarded to research institutes engaged in exosome therapeutics-related projects.
• A detailed analysis of the global events attended by the exosome therapy developers.
• An analysis of the partnerships that have been established in this domain, in the recent past.
• An in-depth analysis of various investments made since 2017.
• An analysis of start-ups / small companies engaged in the development of exosome therapeutics.
• A case study highlighting the companies engaged in offering exosome development and manufacturing services.
• An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development.
• A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of Therapeutic

• Allogeneic Therapy
• AutologousTherapy

Target Indication(s)

• Degenerative Meniscal Injury
• Dystrophic Epidermolysis Bullosa
• Fistula Perianal
• Retinitis Pigmentosa

Therapeutic Area

• Dermatological Disorders
• Muscoskeletal Disorders
• Ophthalmic Diseases
• Rectal Disorders

Route of Administration

• Fistula Tract
• Intra-articular
• Intra-ocular

Geography

• North America
• Europe
• Asia-Pacific and Rest of the World

Key companies covered in the report

• Codiak BioSciences
• Coya Therapeutics
• Curexsys
• EV Therapeutics
• Evox Therapeutics
• SHIFTBIO
• AEGLE Therapeutics
• AVEM Healthcare
• Cellular Biomedicine Group
• OBCTCD24
• ReNeuron
• Stem Cell Medicine

Key Market Insights

• Close to 60 players, worldwide, have taken initiatives to develop exosome therapeutics; the market is characterized by the presence of start-ups and small companies
• The current pipeline features more than 120 exosome therapeutics that are being evaluated across different phases of development; most of these are designed for intravenous administration
• 3,000+ patients have been recruited / enrolled in clinical trials evaluating exosome related therapies and biomarkers across different geographies
• More than 530 grants have been awarded for the ongoing R&D efforts for exosome therapeutics; University of California has been awarded the maximum grant amount of USD 21 million
• A variety of investors, having realized the benefits and future opportunities in this field, have invested more than USD 570 million across more than 30 instances, since 2017
• The rising interest of stakeholders in exosome therapeutics is also reflected by the increasing number of partnerships established by various industry and non-industry players
• Stakeholders have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities existing in this domain
• At present, more than 30 start-ups are driving innovation in this domain; a variety of R&D initiatives have been undertaken by these players over the last few years for the development of exosome therapeutics
• Lack of efficacy, COVID-19 pandemic, limited patient enrollment, and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players
• With the rising demand for therapeutic advances in drug safety, the market of exosome therapeutics is expected to grow at an annualized rate of 41% between 2029–2040
• The projected market opportunity is likely to be well distributed across different routes of administration, types of formulations and key geographical regions

Key Questions Answered

• Who are the leading industry and non-industry players engaged in the development of exosome therapies?
• Which are the key drugs being developed across early and late stages of development?
• What are the key agendas being discussed in various global events / conferences related to exosomes?
• What kind of partnership models are commonly adopted by industry stakeholders?
• Which are the leading funding institutes / centers supporting the research related to exosome therapies?
• Which geographies are the most active in conducting clinical trials related to exosome therapies?
• How is the current and future market opportunity, related to exosome therapies likely to be distributed across key market segments?

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Contact:

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com